Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$1.99, compared with -$1.9 a year earlier. Trailing-twelve-month EPS (Basic) was -$12.89.
Context
- EPS (Basic) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 8 analysts of -$2.02 (+84.3%) for the fiscal year ending Dec 2026, a step up from the +41.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$1.99+38.8% QoQ
- Last fiscal yearDec 2025
- -$12.85+41.3% YoY
- LTMJun 2026
- -$12.89-0.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.7% | +83.0% | +87.7 pp |
| 1 year | +41.3% | +84.3% | +43.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (12.85) USD
- Year-over-year change
- +41.3%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.85) | +41.3% |
| FY2024 | 2024-12-31 | (21.90) | -9.6% |
| FY2023 | 2023-12-31 | (19.99) | -16.0% |
| FY2022 | 2022-12-31 | (17.23) | -17.8% |
| FY2021 | 2021-12-31 | (14.63) | — |
EPS (Basic) vs competitors
How MDGL compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -0.3% is the 4th highest of 7, against a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.93 USD | +26.2% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$1.35 USD | +23.3% | — |
| FY2025 | -€1.82 EUR | +48.6% | — | |
| LTM Jun 2026 | -$2.18 USD | -32.1% | — | |
| LTM Mar 2026 | -$2.75 USD | -4396.9% | — | |
| LTM Jun 2026 | -$4.66 USD | -204.6% | — | |
| LTM Jun 2026 | -$12.89 USD | -0.3% | — | |
| Peer median (excluding MDGL) | — | -4.4% | — | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 180.13M | 958.4M |
| Cost of Revenue | 0 | 0 | 0 | 6.23M | 56.15M |
| Gross Profit | 0 | 0 | 0 | 173.9M | 902.26M |
| Gross Margin | — | — | — | 96.5% | 94.1% |
| Research & Development | 205.16M | 245.44M | 272.35M | 236.72M | 388.53M |
| Selling, General & Admin | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M |
| Operating Expenses | 242.48M | 293.57M | 380.5M | 671.78M | 1.2B |
| Depreciation & Amortization | 405K | 467K | 527K | 1.1M | 1.51M |
| EBITDA | (241.44M) | (290.92M) | (360.39M) | (450.13M) | (264.47M) |
| EBITDA Margin | — | — | — | -249.9% | -27.6% |
| Operating Income | (242.48M) | (293.57M) | (380.5M) | (497.88M) | (300.1M) |
| Operating Margin | — | — | — | -276.4% | -31.3% |
| Interest Income | 363K | 2.19M | 19.58M | 46.65M | 37.36M |
| Interest Expense | 0 | 3.96M | 12.71M | 14.67M | 22.31M |
| Other Income / Expenses | 636K | (1.78M) | 6.87M | 31.98M | 11.81M |
| Income Before Tax | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Pre-Tax Margin | — | — | — | -258.6% | -30.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Net Margin | — | — | — | -258.6% | -30.1% |
| EPS (Basic) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| EPS (Diluted) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| Weighted Avg Shares | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
| Weighted Avg Shares (Diluted) | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.